{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:52:55Z","timestamp":1764510775824,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T00:00:00Z","timestamp":1640476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006004","name":"Tohoku University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2021.100288","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T12:28:32Z","timestamp":1640608112000},"page":"100288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anaplastic multiple myeloma with MYC rearrangement"],"prefix":"10.1016","volume":"17","author":[{"given":"Satoshi","family":"Ichikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyoshi","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ichinohasama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lrr.2021.100288_bib0001","first-page":"166","article-title":"Anaplastic myeloma with massive extramedullary involvement","volume":"51","author":"Foucar","year":"1983","journal-title":"Report of two cases, Cancer"},{"issue":"1","key":"10.1016\/j.lrr.2021.100288_bib0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3960\/jslrt.17035","article-title":"Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission","volume":"58","author":"Ichikawa","year":"2018","journal-title":"J. Clin. Exp. Hematop"},{"issue":"2","key":"10.1016\/j.lrr.2021.100288_bib0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12288-017-0880-2","article-title":"CD38-negative myeloma with anaplastic morphology at presentation: a case report","volume":"34","author":"Singh","year":"2018","journal-title":"Indian J. Hematol. Blood Transfus"},{"issue":"12","key":"10.1016\/j.lrr.2021.100288_bib0004","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s00277-020-04244-7","article-title":"Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy","volume":"100","author":"Tang","year":"2021","journal-title":"Ann. Hematol"},{"issue":"7","key":"10.1016\/j.lrr.2021.100288_bib0005","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00277-013-1950-7","article-title":"Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma","volume":"93","author":"Agrawal","year":"2014","journal-title":"Ann. Hematol"},{"issue":"9","key":"10.1016\/j.lrr.2021.100288_bib0006","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/j.clml.2016.06.008","article-title":"Anaplastic multiple myeloma: an aggressive variant with a poor response to novel therapies","volume":"16","author":"Ammannagari","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.lrr.2021.100288_bib0007","doi-asserted-by":"crossref","unstructured":"W. Tang, Y. Xu, B. Xiang, Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy, Ann. Hematol. (2020).","DOI":"10.1007\/s00277-020-04244-7"},{"issue":"9","key":"10.1016\/j.lrr.2021.100288_bib0008","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/jclinpath-2016-204294","article-title":"Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma","volume":"70","author":"Ahn","year":"2017","journal-title":"J. Clin. Pathol"},{"key":"10.1016\/j.lrr.2021.100288_bib0009","unstructured":"S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S. Pileri, H. Stein, J. Thiele, Z. Swiatowa Organizacja, C. International Agency for Research on, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, Lyon, 2017."},{"issue":"10","key":"10.1016\/j.lrr.2021.100288_bib0010","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2021.100288_bib0011","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cancergen.2018.10.007","article-title":"Clinical impact of MYC abnormalities in plasma cell myeloma","volume":"228-229","author":"Garcia","year":"2018","journal-title":"Cancer Genet"},{"key":"10.1016\/j.lrr.2021.100288_bib0012","doi-asserted-by":"crossref","unstructured":"H.E.H. Moller, B.S. Preiss, P. Pedersen, B. Ostergaard, M. Frederiksen, N. Abildgaard, M.B. Moller, Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma, Eur. J. Haematol. (2018).","DOI":"10.1111\/ejh.13141"},{"issue":"12","key":"10.1016\/j.lrr.2021.100288_bib0013","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.leukres.2013.09.025","article-title":"Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications","volume":"37","author":"Bahmanyar","year":"2013","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.lrr.2021.100288_bib0014","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.lrr.2021.100288_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome Arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.lrr.2021.100288_bib0016","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00277-021-04475-2","article-title":"The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma","volume":"100","author":"Jin","year":"2021","journal-title":"Ann. Hematol"},{"issue":"3","key":"10.1016\/j.lrr.2021.100288_bib0017","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3324\/haematol.2015.136929","article-title":"Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma","volume":"101","author":"Weinhold","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lrr.2021.100288_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3960\/jslrt.19031","article-title":"Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma","volume":"60","author":"Saburi","year":"2020","journal-title":"J. Clin. Exp. Hematop"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048921000558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048921000558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:48Z","timestamp":1761959328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048921000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":18,"alternative-id":["S2213048921000558"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100288","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anaplastic multiple myeloma with MYC rearrangement","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100288"}}